CDC to investigate lung diseases associated with vaping

The CDC is helping a handful of Midwest states investigate a “cluster” of lung diseases related to e-cigarette use, the agency announced Aug. 17.

The investigation follows reports of vaping-related injuries. In recent days, the number of injured people has risen to 120 across 15 states.

The injuries are primarily among young adults and adolescents and are caused by vaping, according to the CVC, which noted 94 cases of severe lung illnesses as of August 15.

The link to e-cigarette use is somewhat vague, though the CDC needs more information “to determine what is causing the illnesses, the agency said.

“There is no conclusive evidence that an infectious disease is causing the illnesses,” the CDC’s announcement read.

E-cigarettes have taken off in popularity over the last several years, particularly among young adults and teenagers. While some studies have found their use can help smokers quit, their health impacts are not totally known and still have harmful effects. Plus, some e-cigarette makers have come under fire for selling flavored products that are geared toward younger consumers.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

A string of executive orders from the White House created serious concerns among radiologists and other healthcare providers throughout the United States. The American College of Radiology issued a statement to help guide its members through the chaos. 

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.